A recently published RCT compared the effects of three months of aromatase inhibitor (letrozole) to that of three months of gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status [70]. This evidence concerns the gene CYP19A1 and Uterine leiomyoma.